Press Releases

Date Title and Summary View
Toggle Summary NxStage® to Report First Quarter 2017 Financial Results
LAWRENCE, Mass. , April 6, 2017 /PRNewswire/ --  NxStage Medical, Inc . (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care , today announced plans to release its financial results for the first quarter ended March 31, 2017 , on Tuesday, May 9, 2017 , before the
View HTML
Toggle Summary New Data Shows Significant Potential Cost Savings with On-Site Hemodialysis in Skilled Nursing Facilities
On-site hemodialysis with NxStage System One provides cost-effective alternative to expensive transportation services associated with off-site dialysis
View HTML
Toggle Summary NxStage Medical Announces CE Mark for its NxGen Hemodialysis System
LAWRENCE, Mass. , March 2, 2017 /PRNewswire/ --  NxStage Medical, Inc . (NASDAQ: NXTM), a leading medical technology company focused on advancing renal care, today announced that its next generation hemodialysis system has received CE Mark approval.  This innovative system consists of new features
View HTML
Toggle Summary NxStage Reports Fourth Quarter and Full-Year 2016 Financial Results
LAWRENCE, Mass. , Feb. 28, 2017 /PRNewswire/ -- Highlights: Full-Year Revenue Increases to $366 million , up 9% from 2015 Full-Year Home Revenue Increases to $209 million , up over 14% from 2015 Full-Year Operating Income from Products Business More than Doubles to $23 million Outlook for 2017
View HTML
Toggle Summary NxStage Announces First Quarter 2017 Investor Conference Schedule
LAWRENCE, Mass. , Feb. 16, 2017 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care , today announced that Jeffrey H. Burbank , Founder and Chief Executive Officer, plans to participate in the following schedule of investor
View HTML
Toggle Summary NxStage Announces Appointment of Chief Medical Officer
Allan J. Collins, M.D., FACP, expands Medical Affairs leadership role within NxStage
View HTML
Toggle Summary NxStage® to Report Fourth Quarter and Full Year 2016 Financial Results
LAWRENCE, Mass. , Jan. 16, 2017 /PRNewswire/ -- NxStage Medical, Inc . (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care , today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2016 , on Tuesday, February
View HTML
Toggle Summary New Data Shows Better Outcomes, Higher Quality of Life, Lower Cost of Care, and Increased Likelihood for Transplant with More Frequent Hemodialysis Using the NxStage System One
Five data presentations to be showcased at ASN Kidney Week 2016
View HTML
Toggle Summary NxStage Reports Third Quarter Financial Results; Raises Full-Year Revenue Guidance And Cuts Net Loss Guidance In Half
-- Q3'16 Revenue and Net Loss Better than Guidance Ranges-- Home Revenue Increases to $53.8 million, up 16% from Q3'15-- Full-Year Revenue Guidance Moves to High End of Previous Range; Net Loss Guidance Improves to a Range of $4 to $5 million-- Company to Launch Next Sequence of NxGen Features and Capabilities
View HTML
Toggle Summary NxStage Announces Fourth Quarter 2016 Investor Conference Schedule
LAWRENCE, Mass. , Nov. 1, 2016 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care , today announced that Jeffrey H. Burbank , Founder and Chief Executive Officer, plans to participate in the following schedule of investor
View HTML